Therapeutic Innovation Is Not Enough: It Still Has to Be Delivered

Pharmaceutical laboratories are piling up favorable signals. GSK highlights 76% complete responses with Jemperli (dostarlimab) in locally advanced MSI-H/dMMR rectal cancer, and a 67% reduction in the risk of progression or death with Ris-Rez versus chemotherapy in relapsed osteosarcoma, in China. Hibsago (bepirovirsen) has also been approved in the United States against chronic hepatitis B. These results, however, come from the manufacturers themselves, and nothing indicates at this stage how they will reach patients.

Biologists as a New Vaccination Channel

In France, the three-year agreement signed on November 3, 2026 between biologists and the national health insurance fund illustrates this shift. Authorized since late 2023 to prescribe and administer certain vaccines, laboratories see their preventive role recognized for 2027-2029. Their asset: 500,000 patients welcomed every day, as many opportunities to propose a vaccination update during a blood test. The health insurance fund's logic is also budgetary: hospital spending linked to influenza ranges between €26 million and €210 million depending on the season, and better vaccination coverage can reduce it.

A Logistical Lock That Caps Ambition

Biologists hope to capture 5% to 10% of the vaccine market in the first year, and up to 15% by 2029 if they obtain the right to store vaccines. Yet they can neither buy nor store them today: patients must arrive with their prescribed dose. Without change before the agreement takes effect in January 2027, the ramp-up will remain modest. These projections come from the profession itself, with no external confirmation, and no data yet documents pharmacists' reaction or actual volumes.

The Same Logic in General Medicine

In Ain, 23 junior doctors in general medicine took up their posts on November 2. They consult three days a week alongside general practitioners, in territories facing difficulties in access to care. Across Auvergne-Rhône-Alpes, 302 internships are distributed across the twelve departments. The pattern is identical: rely on professionals already established rather than create new structures. With their autonomy being gradual, the effect on access to care remains to be measured, for lack of a results indicator.

A Conclusion Proportionate to the Facts

These signals trace a single trend: the health challenge is shifting from developing the molecule to delivering it locally. Legal and financial frameworks are advancing, but they will produce measurable effects only if the vaccine supply barrier is lifted and if the real impact of these new relays is tracked over time.

This article was written with the assistance of artificial intelligence and verified by our editorial team.